days were really very nice because everyone was excited and everyone wanted
to figure out what was going on. Everyone had their own different little
area of expertise. [Dr.] Henry Masur had taken care of AIDS patients in
New York and he was here. Over at the FDA, a guy named [Dr.] Alain Rook,
working with Gerry [Dr. Gerald] Quinnan, had expertise in cytomegalovirus
and the immune response to cytomegalovirus. They were interested in studying
the AIDS patients as well. You had people like myself who were immunology-oriented.
There were people from the Cancer Institute–Ed [Dr. Edward] Gelmann,
who had been in Bob Gallo's lab working on HTLV-1, had left Bob and was
over here [in the Clinical Center], with an interest in the retrovirally
induced diseases. He was working on AIDS before we knew it was a retrovirus.
And there were people like [Dr.] Dan Longo, who were a little bit more
peripheral at that point in time. Dan was interested in lymphomas and
chemotherapeutic regimens, trying to make some contributions. So, there
were a lot of people with different backgrounds coming in who were thrown
together–not just from NIH, but from the FDA as well. [Dr.] Abe
Macher, who was down in Anatomic Pathology at that time, had a strong
interest in what was going on. Abe is one of the people who was bringing
cadavers in to try to understand the disease. He would bring cadavers,
from all round the country, to try to see what kinds of problems the patients
had died of. He was doing his fellowship in pathology at that time. He
had already done a fellowship in infectious diseases. There was a lot
of interaction like that. That was a good time, I think.